B+
Bull case
25%
Probability
Target price
$7.20
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
TSHA
Taysha Gene TherapiesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
REVEAL dosing is complete, earlier Part A follow-up showed functional gains, and the company reported no severe treatment-related serious adverse events or dose-limiting toxicities among 33 treated patients as of its August cutoff. June-quarter cash of $455.4 million and management's runway estimate into 2H 2028 support the planned readout and BLA work.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -3.8.
What can break
Higher R&D spending and future commercialization costs could shorten the company's projected cash runway or lead to additional dilution. [#SEC-8K-2026-08-11]
Momentum
7
Value
41
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.10 · Bull $7.20 · Bear $1.40Analysis 2026-10-15; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-27 • Vendor: Data Vendor v1
Scores
As of 2026-10-27 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-27
Investment thesis
As of 2026-10-27
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-27. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $13.00
Why
Momentum7 · Δ7d +0.3
Value41 · Δ7d -0.1
Sentiment58 · Δ7d -3.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -3.8.
Contradictions & invalidation
- • Higher R&D spending and future commercialization costs could shorten the company's projected cash runway or lead to additional dilution. [#SEC-8K-2026-08-11]
- • Longer-term safety and durability, including in younger ASPIRE patients, remain to be demonstrated. [#SEC-8K-2026-08-11]
- • TSHA-102 remains investigational.
Catalyst clock
2026-12-31
TSHA-102 manufacturing qualification
Lead driver: Sentiment · See AI snapshot
Momentum
7
8% active weight
Current posture
7d trendImproving
Δ7d
+0.3
Δ21d
-5.9
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.3
Sentiment
58
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.8
Δ21d
-28.1
Why this grade
Composite grade D. Momentum 7.1 / Value 40.6 / Sentiment 57.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-15. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$4.10
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-10-15 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-27
Fundamentals (TTM)
As of 2026-10-27
Market Cap
$1.38B
Beta
0.99
Shares Out
325.83M
P/E (TTM) · Derived
-12.5
P/S (TTM)
212.28
P/FCF (TTM) · Derived
-11.06
Rev YoY
-100.0%
EPS YoY
+40.1%
Gross Margin
+78.7%
Op Margin
-1618.5%
Net Debt
-$249.69M
Current Ratio
17.76
As of 2026-10-27 • Updated nightlySource: Internal modelMethods & Data